Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$1.79 - $2.81 $26,850 - $42,150
-15,000 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$2.8 - $6.23 $9,480 - $21,094
3,386 Added 29.15%
15,000 $42,000
Q1 2021

May 17, 2021

BUY
$5.2 - $7.95 $60,392 - $92,331
11,614 New
11,614 $69,000

Others Institutions Holding IKT

About Inhibikase Therapeutics, Inc.


  • Ticker IKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,227,100
  • Market Cap $33.8M
  • Description
  • Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointes...
More about IKT
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.